tbuckley/cabot-search huggingface dataset:
High-dose mitoxantrone-based induction therapy in newly diagnosed AML. Results of 171 patients treated at NYMC between 1991–2003
Authors: K. Seiter, D. Liu, E. Feldman, Q. Shi, A. Qureshi, P. Baskind, M. Arshad, T. Ahmed
Journal: Journal of Clinical Oncology (2004)

6610 Background: We developed a high dose mitoxantrone(M)-based induction regimen based on the steep dose-response curve for M. Methods: 171 newly dx'd AML pts were rx'd on 4 trials between 1991–2003. Study 1: Phase II study, age <60. Induction: M 80 mg/m2 x 1, ara-C (A) 3 gm/m2/d x 5, VP-16 (V) 150 mg/m2/d qod x 3. Consolidation: 5 mos A x 4d with M 20 mg/m2 mos 3 + 5, V 150 mg/m2 x 2 mos 4 + 6. Study 2: randomized study of high vs standard dose M with A in pts ≥ 60 yrs. Pts did not receive consolidation. Only pts with high dose M are included here. Study 3: Same as study 1 except pts received ATRA 45 mg/m2 x 3 doses. Pts < 60 received consolidation as in study 1. Pts ≥ 60 did not receive consolidation. Study 4: Pts ≥60 yrs, same as study 2 + temozolomide postremission therapy. In each study, pts with prior antecedent hematologic disorder (AHD) or secondary AML were included. Results: Median age: 59 (21–88); M/F: 91/80; cytogenetics(SWOG): good:13%, intermediate:50%, poor:26%, indeterminate:5%, IM:6%; Prior AHD: 32% of pts. Response: Pts < 60 yrs: CR 79%, failure (F):18%, toxic death (TD):3%; Pts ≥60: CR 52%, F 34%, TD 14%. CR without AHD: 78%, with AHD: 44%. CR by cytogenetic group: good: 91%, int: 67%, poor: 50%, indeter: 63%. Median duration of response (DOR) is 24 mos (range 1–139+ mos) for pts < 60 yrs, and 8 mos (1–66+ mos) for pts ≥ 60. Overall survival (OS) is 19 mos (0–139+ mo) for pts < 60 and 7.6 mos (0–66+ mos) for pts ≥ 60 yrs. For pts without AHD < 60 yrs, median DOR is 38.9 mos and median OS is 24 mos. Conclusions: High dose M-based therapy yields high response rates and high percentage of durable remissions even in poor risk patients, many of whom would not be eligible for typical US AML trials. No significant financial relationships to disclose.
Comorbidity: Usage of, and survival after chemotherapy for advanced lung cancer.
Authors: Anders Mellemgaard, Philomena Bredin, Maria Iachina, Anders Green, Mark Krasnik, Erik Jakobsen, Margreet Lüchtenborg, Henrik Møller
Journal: Journal of Clinical Oncology (2013)

e19157 Background: Comorbidity may influence prognosis in lung cancer, affect performance status (PS) of patients as well as complicate treatment. The present study examines usage and outcome of chemotherapy (CT) for advanced-stage lung cancer, and focuses on the role of comorbidity. Methods: Patients with advanced-stage lung cancer were identified in the Danish Lung Cancer Registry. A total of 22,999 patients with non-resectable, advanced-stage lung cancer were identified. Data on stage, PS, Charlson comorbidity score (ChS), age, histology and type of first treatment (if any) were avaliable. First treatment was categorized as chemotherapy (n=7,346), chemo-radiotherapy (2,636), radiotherapy (n=4,155) or no therapy (n=8,862). Survival was examined separately for 0-1 year and 1-5 years, and further distinction was made between metastatic and non-metastatic lung cancer. Data are presented for the subgroup of patients receiving chemotherapy as first treatment only. All estimates are derived from logistic regression model adjusting for the effect of performance status, pulmonary function and histological type, except for usage where models included same variables plus stage. Results: Use of chemotherapy was less frequent for more comorbid patients (OR 0.86, 0.64, 0.56 for Charlson score 1, 2, 3+ respectively compared to no comorbidity). Older patients and men were less likely to receive CT. For patients receiving CT as first treatment for non-metastatic lung cancer, survival in the first year was slightly worse for those with co-morbidity (HR 0-1year, non metastatic =0.91, 0.92, 0.87 for ChS 1,2,3+ respectively). For 1-5years and for metastatic lung cancer no correlation between comorbidity and survival was noted. In contrast, PS and sex was strongly associated with survival. Conclusions: With increasing co morbidity, chemotherapy was used less often. Comorbidity is not an important prognostic factor in advanced lung cancer treated with chemotherapy. However, sex and especially performance status remain as strong prognostic factors in this patient group.
COMPARISONS OF FLOW-GRADIENT PATTERNS IN SEVERE AORTIC STENOSIS BETWEEN BICUSPID AORTIC VALVES AND TRICUSPID AORTIC VALVES
Authors: Darae Kim, Chi Young Shim, In-Jeong Cho, Hyuk-Jae Chang, Geu-Ru Hong, Jong-Won Ha, Namsik Chung
Journal: Journal of the American College of Cardiology (2017)
SAFETY AND FEASIBILITY OF ROTATIONAL ATHERECTOMY IN ELDERLY PATIENTS WITH SEVERE AORTIC STENOSIS AND CALCIFIC CORONARY ARTERY DISEASE UNDERGOING EVALUATION FOR TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Matthew Lippmann, Jigar Patel, Jared Kvapil, Michael Pierpoline, Peter Tadros, Mark Wiley, Matthew Earnest, Ashwani Mehta, Eric Hockstad, Kamal Gupta
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF RENIN-ANGIOTENSIN SYSTEM BLOCKADE THERAPY AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: INSIGHTS FROM THE OCEAN-TAVI MULTICENTER REGISTRY
Authors: Tomoki Ochiai, Shigeru Saito, Futoshi Yamanaka, Koki Shishido, Yutaka Tanaka, Shinichi Shirai, Norio Tada, Motoharu Araki, Toru Naganuma, Yusuke Watanabe, Masanori Yamamoto, Kentaro Hayashida
Journal: Journal of the American College of Cardiology (2017)
IS A PULSATILE GLENN AN ADEQUATE ALTERNATIVE FOR LONG-TERM PALLIATION IN PATIENTS WITH SINGLE VENTRICLE PHYSIOLOGY?
Authors: Carlos M. Mery, Martin A. Chacon-Portillo, Huirong Zhu, Heather Dickerson, Iki Adachi, Jeffrey Heinle, Lauren Kane, Emmett McKenzie, Charles Fraser
Journal: Journal of the American College of Cardiology (2017)
Improved Outcome of Unrelated Cord Blood Transplantation in Children with Severe Aplastic Anemia
Authors: Kazuko Kudo, Hideki Muramatsu, Nao Yoshida, Ryoji Kobayashi, Hiromasa Yabe, Mikiya Endo, Masami Inoue, Yozo Nakazawa, Jun-ichi Hara, Shinji Kaminami, Jiro Inagaki, Yoshiko Hashii, Koji Kato, Ken Tabuchi, Seiji Kojima
Journal: Blood (2016)
Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts) with advanced solid tumors.
Authors: Anas Gazzah, Valentina Boni, Jean-Charles Soria, Esther Holgado, Caroline Even, Mahmoud Ould Kaci, Serge Nazabadioko, Wenqiong Xue, Emiliano Calvo
Journal: Journal of Clinical Oncology (2015)

2536 Background: Afatinib combined with cetuximab has shown activity in pts with EGFRmutation-positive NSCLC and acquired resistance to EGFR tyrosine kinase inhibitors. Targeting the ErbB pathway may also be beneficial in other tumor types; for example, squamous cancers have high levels of EGFR overexpression. This Phase Ib study assessed afatinib plus standard-dose cetuximab in pts with other advanced solid tumors. Methods: In Part A, a 3+3 design was used to determine the maximum tolerated dose (MTD) of afatinib (from 30 to 40 mg daily) plus cetuximab (400 mg/m2 loading dose followed by 250 mg/m2weekly). Treatment was administered until disease progression or unacceptable toxicity. Dose-limiting toxicities (DLTs) in cycle 1 were used to determine MTD. In Part B, MTD was assessed in 3 expansion cohorts (squamous NSCLC, squamous cell carcinoma of head and neck [HNSCC], other tumors). Results: In Part A, 3 pts received afatinib 30 mg in cohort 1, and 6 received afatinib 40 mg in cohort 2. No DLTs were observed in either cohort; MTD was defined as afatinib 40 mg once daily plus standard-dose cetuximab. In Part B, 39 pts have been treated to date at MTD (7 squamous NSCLC, 9 HNSCC and 23 other). Pts were heavily pre-treated (median 3 lines of prior therapy). Among the 45 pts receiving afatinib 40 mg, the most frequent drug-related adverse events (AEs; all grades [G], n [%]) were rash/acne (37 [82%]), diarrhea (28 [62%]), stomatitis (16 [36%]) and fatigue (13 [29%]). 12 pts had drug-related G3 AEs (most commonly rash/acne (5 [11%]) and fatigue (2 [4%]). There were 2 drug-related G4 AEs (hyperlipasemia and hypersensitivity) and no drug-related G5 AEs. Preliminary efficacy results showed that 38% of pts in the expansion cohort had stable disease (SD); 4/7 (57%) in squamous NSCLC, 3/9 (33%) in HNSCC, 8/23 (35%) in other tumors; no objective responses have been reported to date. Median duration of disease control was 12 weeks. Conclusions: MTD was defined as afatinib 40 mg once daily plus cetuximab 250 mg/m2 weekly (after 400 mg/m2 loading dose). At MTD, AEs were mild-to-moderate with no unexpected AEs. SD was observed in 38% of heavily pre-treated pts with squamous NSCLC, HNSCC, and other tumor types. Updated efficacy results will be presented. Clinical trial information: NCT02020577.
Connect MM: The multiple myeloma (MM) disease registry—Incidence of second primary malignancies (SPM).
Authors: Robert M. Rifkin, Rafat Abonour, Rafael Fonseca, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, Chris L Pashos, Sachdev P Thomas, Jatin J. Shah, Howard R. Terebelo, Kathleen Toomey, Neil Minton, Shankar Srinivasan, Thomas Street, Kristen Sullivan, Brian G. Durie
Journal: Journal of Clinical Oncology (2012)

8037 Background: Advances in the treatment of MM have greatly improved clinical outcomes for patients (pts). SPM occurrence has been observed in early and late stage MM as well as with increasing age. US SEER Cancer Registry reports a background incidence rate of SPM 2.1/100 person-yrs (PY) among persons ≥ 65 yrs of age. However, incidence of SPM in MM pts and the relationship to therapy still warrants further exploration. Methods: Connect MM is a US-based observational registry designed to characterize pts with newly diagnosed MM from 266 US sites. Initiated in Sep 2009, patient data were collected at baseline and each subsequent quarter with a standardized form. On Dec 14, 2011, Connect MM reached full enrollment at 1,500 pts. Results: As of Jan 13, 2012, preliminary retrospective SPM data is available for 1015 pts. Median age was 67 yrs, 56.8% male, and median follow-up was 10.6 mo (0.03-24.9 mo). 12 pts (7 male) with median age of 68.5 yrs developed SPM. Median time to SPM was 8.5 mo (0.8-17.7 mo) after treatment initiation. 11 invasive SPM were observed - 4 hematological (heme): 1 AML, 1 MDS, 1 CMML and 1 DLBCL, and 7 solid: 2 melanoma skin, 1 bronchus, 1 breast, 1 prostate, 1 tonsil, and 1 gastric carcinoid. Also, 1 pt had non-melanoma skin cancer (NMSC), and 1 pt with invasive skin cancer also had NMSC. Of the 4 pts developing heme SPM, 3 had bortezomib (BORT), 1 had thalidomide (THAL), 1 had lenalidomide (LEN), 2 had melphalan (MEL), and all 4 pts had steroids. Of the 7 pts who developed solid tumor SPM, 5 had BORT, 5 had LEN, 2 had doxorubicin, 1 had MEL, 5 had steroids, 1 had irradiation, and 1 had not received MM treatment. 2 pts with prior history of invasive malignancy developed solid tumor SPM (1 pt also developed NMSC).1 pt who received irradiation developed NMSC. Early overall incidence of invasive SPM was 1.21/100 PY (95% CI 0.60, 2.16) for all pts and 1.20/100 PY (95% CI 0.44,2.62) for pts ≥ 65 yrs of age. Conclusions: This preliminary analysis shows that SPM occurred at an expected rate in this disease specific registry of patients with NDMM and appeared to occur irrespective of MM treatment administered. Incidence rates of SPM may increase over time as patients receive transplantation and alkylators. Prospective observation will continue.
A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas
Authors: J. J. Raizer, S. Grimm, L. Rice, K. Muro, J. Chandler, C. Tellez, A. L. Mellot, S. Newman, M. K. Nicholas, M. Chamberlain
Journal: Journal of Clinical Oncology (2009)

2044 Background: Increasingly target specific agents are used in the treatment of malignant gliomas (MG). Among targeted agents, bevacizumab appears most promising and when combined with CPT-11. As CPT-11 has limited activity in recurrent MG, a single agent phase II trial of bevacizumab given every 3 weeks in with recurrent MG was performed. Methods: All patients (pts) had to sign an IRB informed consent except six pts who were treated at a different site in a similar fashion. All pts had to have at least one relapse with the first sixteen required to have two relapses before protocol amendment. Inclusion criteria required &gt; 18 year of age, KPS &gt; 60, on a non-enzyme inducing anticonvulsant, adequate bone marrow, liver and renal function, and normal urine protein and creatinine. MRI with perfusion was done at baseline (if patient consented) and then every 6 weeks. Patients were assessed using Macdonald criteria and continued on trial until tumor progression or toxicity. Treatment was bevacizumab 15 mg/kg every 3 weeks. Results: 61 patients (35 male; 26 female; 50 GBM, 5 AA, 6 AO/AOA) with a median age of 51 were treated. Median number of doses given was 4 (range 1–18). PFS-6 was 32% (median PFS was 3.9 m; median OS was 6.6 m). Best radiographic response included 0% CR, 25% PR and 50% SD. Grade 3+ toxicities were non-fatal intracranial hemorrhage (1), fatal GI perforation (1), DVT (1), fatigue (4), rectal bleeding (1), weakness (1), and lack of drive (1). Conclusions: Bevacizumab as a single agent given every 3 weeks at 15 mg/kg is effective and safe for recurrent MG. The observed PFS-6 and OS is lower than reported bevacizumab regimens administered every 2 weeks; this difference may be related to patient selection. [Table: see text]
INCIDENCE, PREDICTIVE AND PROGNOSTIC FACTORS OF HOPITALIZATION FOR CONGESTIVE HEART FAILURE IN PATIENTS IMPLANTED WITH TAVR BETWEEN 2010 AND 2014 AT ROUEN UNIVERSITY HOSPITAL.
Authors: Maxime Doutriaux, Nicolas Bettinger, Najime Bouhzam, Christophe Tron, Bastien Glinel Mortreuil, Fabrice Bauer, Eric Durand, Helene Eltchaninoff
Journal: Journal of the American College of Cardiology (2017)
RESECCIÓN MUCOSA ENDOSCÓPICA DE PÓLIPOS YUXTA-HEMORROIDALES
Authors: E Oblitas Susanibar Elida, C Guarner Argente, M Concepción, J Colan, M Martinez, P Huelin, J Gordillo, C Gómez, S Sáinz, C Guarner Aguilar
Journal: Endoscopy (2015)

Introducción: La resección mucosa endoscópica (RME) es el método de elección para resección de lesiones superficiales del colon. El manejo de lesiones de localización yuxtahemorroidal es controvertida por la dificultad de delimitación y abordaje de la lesión y la extensión difusa. Sin embargo, esta también es una limitación para otras técnicas como la disección submucosa o la cirugía (Transanal endoscopic microsurgery). La maniobrabilidad del gastroscopio puede permitir un buen acceso.
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the<scp>EMPHASIS‐HF</scp>trial
Authors: Arnaud Olivier, Bertram Pitt, Nicolas Girerd, Zohra Lamiral, Jean‐Loup Machu, John J.V. McMurray, Karl Swedberg, Dirk J. van Veldhuisen, Timothy J. Collier, Stuart J. Pocock, Patrick Rossignol, Faiez Zannad, Anne Pizard
Journal: European Journal of Heart Failure (2017)
CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival
Authors: Suma Yaddanapudi, Mehmet M. Altintas, Andreas D. Kistler, Isabel Fernandez, Clemens C. Möller, Changli Wei, Vasil Peev, Jan B. Flesche, Anna-Lena Forst, Jing Li, Jaakko Patrakka, Zhijie Xiao, Florian Grahammer, Mario Schiffer, Tobias Lohmüller, Thomas Reinheckel, Changkyu Gu, Tobias B. Huber, Wenjun Ju, Markus Bitzer, Maria P. Rastaldi, Phillip Ruiz, Karl Tryggvason, Andrey S. Shaw, Christian Faul, Sanja Sever, Jochen Reiser
Journal: Journal of Clinical Investigation (2012)

During the preparation of this manuscript, the fourth row of images in Figure 5C
ETIOLOGY, PATIENT CHARACTERISTICS AND SURGICAL OUTCOMES OF ACUTE SEVERE AORTIC REGURGITATION
Authors: Mohammad Maysara Asfari, Serge Harb, Yuping Wu, Andrew Higgins, Gosta Pettersson, Steve Gordon, Brian Griffin, Nabin Shrestha, Wael Jaber, Venu Menon
Journal: Journal of the American College of Cardiology (2017)
APPLICATION OF DAPT SCORE TO PREDICT ISCHEMIC AND BLEEDING EVENTS IN JAPANESE PATIENTS UNDERGOING DRUG-ELUTING STENT IMPLANTATION: AN OBSERVATION FROM A POOLED COHORT OF THE CREDO-KYOTO COHORT-2, RESET, AND NEXT TRIALS
Authors: Yusuke Yoshikawa, Hiroki Shiomi, Hirotoshi Watanabe, Masahiro Natsuaki, Hirokazu Kondo, Toshihiro Tamura, Takeshi Morimoto, Yoshihisa Nakagawa, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2017)
Group Psychotherapy with Drug Addicts and Alcoholics / Gruppenpsychotherapie und medizinische Praxis / Group-Psychotherapy and its Technique / Social Psychiatry / Group-Psychotherapy with Delinquents
Authors: E.J. Anthony, G.W. Arendsen Hein, Dorothy W. Baruch, R. Battegay, Cornelius Beukenkamp, Åke Bjerstedt, Nathan Blackman, Curt Boenheim, Rachel B. Bross, Martha Brunner-Orne, José Angel Bustamante, Udo Derbolowsky, R.S. Drews, G. Egan, I. Frost, Henry Ezriel, C.M. Fleming, Hellmuth Freyberger, D. Fuchs-Kamp, H. Gastager, Henry Raphael Gold, Henry Greenbaum, S. Haddenbrock, Angela Hefferman, Thomas Hora, Asya L. Kadis, Berthold Kihn, F. Knobloch, D. Langen, Karl Hermann Lukas, Michael M. Miller, Theresa G. Muller, Jean Oury, Walter Zenner, Helmut Paul, Hertha Riese, Stefan de Schill, P.-B. Schneider, M. Barrelet, P. Jordi, R. Delaloye, Paul Senft, Gerdhild von Staabs, Mark Stern, Herbert Suchanek-Fröhlich, J. Wilder, Alexander Wolf, Emanuel K. Schwartz, Isidore Ziferstein, Manfred in der Beeck, Jack D. Krasner, G.A. Leutz, Margaret Naumburg, Janet Caldwell, Louis R. Ormont, G. Stürup, Ernst von Xylander
Journal: Psychotherapy and Psychosomatics (1959)
Low-dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for newly diagnosed multiple myeloma
Authors: G. Teoh, D. Tan, C. Chuah, W. Hwang, R. Yiu, P. Kuperan, S. Tien, L. Lee, A. Ang, G. Kam
Journal: Journal of Clinical Oncology (2007)

18506 Background: Although dexamethasone (Dex), thalidomide (Thal) and zoledronic acid (Zol) have frequently been combined for the treatment of multiple myeloma (MM), the ideal dosing schedule is unknown. We previously reported that lower doses of Dex and Thal can be effectively combined with high-frequency dosing of Zol (Haematologica 2005). Methods: This “dtZ” regimen - which comprises weekly Dex 20 mg OM for 4 days, Thal 50 mg ON, and 3-weekly Zol 4 mg - resulted in an impressive response rate (RR) of 61.6% and near complete remission (nCR)/complete remission (CR) rate of 7.7% in 26 patients with relapsed/refractory MM. Results: In this present study, we treated 22 newly diagnosed MM patients with “dtZ” and report an even more impressive RR of 100.0% and nCR/CR rate of 20–35%. The median time to response was 1.8 months and median time to maximum response was 2.2 months. The median time to progression (TTP) has not been achieved yet. As expected, low-dose Dex/Thal resulted in lower (18.1%) grade 3 or 4 toxicities. These were all infections; which lead to further dose-reduction of Dex. There were no thromboembolic events, despite the fact that aspirin was not routinely given. Of particular interest, 3- weekly Zol was not associated with any significant decrease in renal function, and none of our patients developed osteonecrosis of the jaw (ONJ). In fact, at the time of writing of this abstract, more than 1,000 doses of Zol had been administered in a 3-weekly fashion to these as well as other patients, and only 1 patient developed ONJ. This patient who had already received greater than 20 doses of Zol healed uneventfully after receiving appropriate outpatient dental treatment, and subsequently received another 8 doses of Zol with no recurrence of ONJ. Conclusion: In conclusion, the Zol-based “dtZ” regimen is potentially a highly-effective and safe frontline regimen for MM. Using Zol every 3 weeks with lower doses of Dex and Thal does not appear to increase the rate or severity of nephrotoxicity or ONJ. Although we do not know exactly why every patient responded to “dtZ”, we speculate that this could be due to a critical balance that has been achieved between the anti-MM, anti-osteoclastic and immunostimulatory effects of the individual drugs of the combination. No significant financial relationships to disclose.
WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia
Authors: Michele Malagola, Crisitina Skert, Enrico Morello, Francesca Antoniazzi, Erika Borlenghi, Alessandro Turra, Chiara Pagani, Rossella Ribolla, Valeria Cancelli, Federica Cattina, Elisa Alghisi, Simona Bernardi, Simone Perucca, Andrea Di Palma, Giuseppina Ruggeri, Giuseppe Rossi, Luigi Caimi, Domenico Russo
Journal: Blood (2014)
DIFFERENCES AND LEVEL OF AGREEMENT IN SYNTAX SCORE ASSESSMENT BETWEEN SITE OPERATORS AND ANGIOGRAPHIC CORE LABORATORY READERS: INSIGHTS FROM THE EXCEL TRIAL
Authors: Philippe Genereux, Patrick Serruys, A. Kappetein, Ad Van Boven, Mark Hickey, David Kandzari, Erick Schampaert, Ovidiu Dressler, Imre Ungi, Samer Mansour, Adrian Banning, David Taggart, Manel Sabate, Anthony Gershlick, Andrzej Bochenek, Jose Pomar, Piet Boonstra, Nicholas Lembo, John Puskas, W. Morris Brown, Roxana Mehran, Ori Ben-Yehuda, Charles Simonton, Joseph Sabik, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
ANTITHROMBOTIC THERAPY DIFFERENCES AND ASSOCIATED OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Ron Waksman, M. Chadi Alraies, Kyle Buchanan, Edward Koifman, Homam Moussa Pacha, Arie Steinvil, Toby Rogers, Jiaxiang Gai, Rebecca Torguson, Michael Gaglia, Itsik Ben-Dor, Augusto Pichard, Lowell Satler
Journal: Journal of the American College of Cardiology (2017)